1.20
0.00 (0.00%)
| Previous Close | 1.20 |
| Open | 1.19 |
| Volume | 33,167 |
| Avg. Volume (3M) | 282,963 |
| Market Cap | 53,792,644 |
| Price / Sales | 27.92 |
| Price / Book | 0.730 |
| 52 Weeks Range |
| Operating Margin (TTM) | -3,904.19% |
| Diluted EPS (TTM) | -1.63 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 50.53% |
| Current Ratio (MRQ) | 7.45 |
| Operating Cash Flow (TTM) | -56.19 M |
| Levered Free Cash Flow (TTM) | -34.04 M |
| Return on Assets (TTM) | -30.49% |
| Return on Equity (TTM) | -76.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Werewolf Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.08% |
| % Held by Institutions | 63.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sphera Funds Management Ltd. | 31 Dec 2024 | 626,810 |
| Dc Funds, Lp | 31 Dec 2024 | 589,102 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (HC Wainwright & Co., 1,150.00%) | Buy |
| Median | 8.00 (566.67%) | |
| Low | 4.00 (JMP Securities, 233.33%) | Buy |
| Average | 9.00 (650.00%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 1.27 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Mar 2025 | 15.00 (1,150.00%) | Buy | 1.23 |
| Wedbush | 12 Mar 2025 | 8.00 (566.67%) | Buy | 1.23 |
| JMP Securities | 14 Jan 2025 | 4.00 (233.33%) | Buy | 1.35 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Mar 2025 | Announcement | Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 04 Mar 2025 | Announcement | Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference |
| 24 Feb 2025 | Announcement | Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors |
| 13 Jan 2025 | Announcement | Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |